About Cyfuse
Cyfuse is a company based in Bunkyo (Japan) founded in 2010.. Cyfuse has raised $16.56 million across 2 funding rounds from investors including Shibuya Kogyo, m3.com and Cyberdyne. The company has 21 employees as of December 31, 2024. Cyfuse operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others.
- Headquarter Bunkyo, Japan
- Employees 21 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cyfuse Biomedical K.K.
-
Annual Revenue
$346.93 K (USD)-10.91as on Dec 31, 2024
-
Net Profit
$-5.56 M (USD)-48.03as on Dec 31, 2024
-
EBITDA
$-5.48 M (USD)-30.46as on Dec 31, 2024
-
Total Equity Funding
$16.56 M (USD)
in 2 rounds
-
Latest Funding Round
$11.76 M (USD), Series B
Feb 27, 2015
-
Investors
Shibuya Kogyo
& 11 more
-
Employee Count
21
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cyfuse
Cyfuse is a publicly listed company on the TSE with ticker symbol 4892 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Cyfuse
Cyfuse has successfully raised a total of $16.56M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $11.76 million completed in February 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $11.8M
-
First Round
First Round
(23 Jan 2013)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2015 | Amount | Series B - Cyfuse | Valuation | Cyberdyne , Shibuya Kogyo | |
| Jan, 2013 | Amount | Series A - Cyfuse | Valuation | UTEC |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cyfuse
Cyfuse has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Shibuya Kogyo, m3.com and Cyberdyne. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and Early stage VC firm investing in Japan
|
Founded Year | Domain | Location | |
|
Venture capital services are provided to support startups and innovation.
|
Founded Year | Domain | Location | |
|
Venture capital investments are provided to innovative startups by DBJ Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cyfuse
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cyfuse
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cyfuse Comparisons
Competitors of Cyfuse
Cyfuse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Desktop bioprinter for genes and proteins production is developed.
|
|
| domain | founded_year | HQ Location |
3D bioprinters and bioinks are developed for research applications.
|
|
| domain | founded_year | HQ Location |
Bioprinting technology and tissue therapeutics for regenerative medicine are developed.
|
|
| domain | founded_year | HQ Location |
Provider of 3D printing of tissue biomaterials for medical research and clinical applications
|
|
| domain | founded_year | HQ Location |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| domain | founded_year | HQ Location |
Developer of integrated 3D printing and tissue-engineering platform
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cyfuse
Frequently Asked Questions about Cyfuse
When was Cyfuse founded?
Cyfuse was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Where is Cyfuse located?
Cyfuse is headquartered in Bunkyo, Japan. It is registered at Bunkyo, Tokyo, Japan.
Who is the current CEO of Cyfuse?
Shizuka Akieda is the current CEO of Cyfuse.
Is Cyfuse a funded company?
Cyfuse is a funded company, having raised a total of $16.56M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.8M, raised on Jan 23, 2013.
How many employees does Cyfuse have?
As of Dec 31, 2024, the latest employee count at Cyfuse is 21.
What is the annual revenue of Cyfuse?
Annual revenue of Cyfuse is $346.93K as on Dec 31, 2024.
What does Cyfuse do?
Founded in 2010 and based in Bunkyo, Japan, Cyfuse focuses on the biotechnology sector through 3D bioprinters. The Regenova system is utilized for producing three-dimensional tissues and organs, while the Spike device is employed to assemble spheroids into custom shapes. These tools support advancements in regenerative medicine and drug discovery processes. Operations emphasize automated fabrication to aid research and development in tissue engineering.
Who are the top competitors of Cyfuse?
Cyfuse's top competitors include Nuclera Nucleics, Aspect Biosystems and Collplant.
Is Cyfuse publicly traded?
Yes, Cyfuse is publicly traded on TSE under the ticker symbol 4892.
Who are Cyfuse's investors?
Cyfuse has 12 investors. Key investors include Shibuya Kogyo, m3.com, Cyberdyne, UT-EC Japan, and JAFCO Group.
What is Cyfuse's ticker symbol?
The ticker symbol of Cyfuse is 4892 on TSE.